Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Economic evaluation of plerixafor for stem cell mobilization
Steven M. Kymes
,
Iskra Pusic
, Dennis L. Lambert
, Martin Gregory
, Kenneth R. Carson
,
John F. DiPersio
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Bursky Center for Human Immunology and Immunotherapy
Department of Medicine
Division of Oncology
Center of Regenerative Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
30
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Economic evaluation of plerixafor for stem cell mobilization'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Allogeneic Peripheral Blood Stem Cell Transplantation
50%
Clinically Significant Change
16%
Cost-effectiveness
16%
Cost-utility
16%
Diffuse Large B-cell Lymphoma (DLBCL)
66%
Economic Evaluation
100%
Expected Lifetime
16%
Failure Rate
16%
Granulocyte Colony-stimulating Factor (G-CSF)
66%
Heavily Pretreated
16%
High-dose Chemotherapy
16%
Incremental Cost-effectiveness Ratio
33%
Lifetime Cost
16%
Lymphoma Patients
66%
Markov Model
16%
Medicare
16%
Microsimulation
16%
Mobilization Regimen
16%
Non-Hodgkin Lymphoma
33%
Phase I Study
16%
Plerixafor
100%
Preferred Treatment
16%
Process of Care
16%
Quality-adjusted Life Years
33%
Relapsed/refractory Hodgkin Lymphoma
16%
Remaining Lifetime
16%
Sensitivity Analysis
16%
Stem Cell Mobilization
100%
University of Washington
16%
Utility Evaluation
16%
Medicine and Dentistry
Autologous Peripheral Blood Stem Cell Transplantation
50%
Diffuse Large B-Cell Lymphoma
66%
Granulocyte Colony Stimulating Factor
66%
Health Care Cost
100%
High Dose Chemotherapy
16%
Lifespan
33%
Medicare
16%
Non-Hodgkin Lymphoma
50%
Plerixafor
100%
Quality Adjusted Life Year
33%
Stem Cell Mobilization
100%